Clinical trial
A Study to Evaluate Lumasiran in Patients With Advanced Primary Hyperoxaluria Type 1 (ILLUMINATE-C)
A Study to Evaluate Lumasiran in Patients With Advanced Primary Hyperoxaluria Type 1 (ILLUMINATE-C)
The purpose of this study is to evaluate the efficacy, safety, pharmacokinetics (PK), and pharmacodynamics (PD) of lumasiran in patients with Advanced Primary Hyperoxaluria Type 1 (PH1).
Study Type: Interventional (Clinical Trial)
Estimated Enrollment: 20 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: ILLUMINATE-C: A Single Arm Study to Evaluate Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Lumasiran in Patients With Advanced Primary Hyperoxaluria Type 1 (PH1)
Actual Study Start Date: January 21, 2020
Estimated Primary Completion Date: May 2021
Estimated Study Completion Date: July 2025
Arm:
- Experimental: Lumasiran
| Category | Value |
|---|---|
| Study type(s) | Interventional |
| Expected enrolment | 20 |
| Actual Study start date | 21 January 2020 |
| Estimated Study Completion Date | 01 July 2025 |